AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
Broad product license acquired for breakthrough DNA-based vaccine.
2003 JUN 18 - (NewsRx.com & NewsRx.net) -- In a windfall step that prominently places the company at the center of DNA-based HIV vaccine development, CytRx Corporation (CYTR) announced it has licensed, from the University of Massachusetts Medical School (UMMS), the exclusive worldwide commercial rights to a novel DNA-based HIV vaccine.
Additionally, $15 million has been awarded from the U.S. National Institutes of Health (NIH) earmarked specifically for the phase I clinical study and evaluation of this vaccine technology.
"In the last decade there has been significant interest in and investment devoted to AIDS vaccine research and we believe the UMMS technology currently stands at the forefront of DNA-based HIV vaccine development," said Steven A. Kriegsman, the company's chief executive officer.
"With this license, which includes a pending patent application with broad coverage claims, CytRx is in a strong and enviable position with regard to future products that leverage the potential of DNA-based HIV vaccines. We are very excited that our vaccine technology is incorporated in the NIH funded clinical study to begin within the next 6 months." Kriegsman noted that if the study is successful, it should open the door for further funding in more advanced clinical trials.
The lead vaccine candidates under development by Shan Lu, MD, PhD, associate professor of medicine at UMMS, seek to overcome certain obstacles that have challenged other HIV vaccine strategies. Among the challenges are the uses of antigens from laboratory strains of HIV or limited viral isolates that do not necessarily represent active strains existing in patients. ...
- CytRx Acquires Broad Product License for Breakthrough DNA-Based HIV Vaccine; -...
- Press release article from: PR Newswire May 21, 2003 700+ words
...company at the center of DNA-based HIV vaccine development, CytRx Corporation...commercial rights to a novel DNA-based HIV vaccine. Additionally, $15 million...stands at the forefront of DNA-based HIV vaccine development," said Steven...
- CytRx acquires product license for breakthrough DNA-based HIV vaccine-.
- Newspaper article from: BIOTECH Patent News May 1, 2003 700+ words
...company at the center of DNA-based HIV vaccine development, CytRx Corporation...commercial rights to a novel DNA-based HIV vaccine. Additionally, $15 million...stands at the forefront of DNA-based HIV vaccine development," said Steven...
- Targeted Genetics Named as Subcontractor to NIAID Contract to Expand AAV-Based...
- Press release article from: Business Wire November 28, 2005 700+ words
...contract to expand AAV-based HIV vaccine development. This...to develop an AAV-based HIV vaccine for worldwide use...an ongoing Phase I HIV Vaccine clinical study in Belgium...tgAAC09, its AAV-based HIV/AIDS vaccine, in...
- NIAID media availability: New strategy proposed for designing antibody-based...
- Newspaper article from: NewsRx Health & Science July 5, 2009 700+ words
...research directions for the development of an antibody-based HIV vaccine, according to John R. Mascola, M.D., deputy...antibodies for the ultimate design of an antibody-based HIV vaccine. Key aspects of this strategy include Obtaining new...
- License will enable CytRx to pursue DNA-based HIV vaccine....
- Magazine article from: Chain Drug Review June 30, 2003 700+ words
...a breakthrough toward a DNA-based HIV vaccine. A Phase I clinical trial is...stands at the forefront of DNA-based HIV vaccine development. "With this license...leverage the potential of DNA-based HIV vaccines. We are excited that...
- Recombinant adeno-associated virus (rAAV)-based HIV vaccine shows promise.
- Newspaper article from: Virus Weekly April 29, 2003 700+ words
...a recombinant adeno-associated virus (rAAV)-based HIV vaccine resulted in robust and sustained antibody and T...both a T-cell and antibody response to our AAV-based HIV vaccine. We believe that this dual response is necessary...
- Experimental DNA-based HIV vaccine. (In the Pipeline).(Brief Article)
- Newspaper article from: Drug Utilization Review April 1, 2002 700+ words
...technology is incorporated in an experimental DNA-based HIV vaccine being developed by Merck & Co. that has now...clinical trials will lead to the development of an HIV vaccine that can effectively prevent or attenuate the development...
- T cell-based HIV vaccine candidate demonstrates positive results.
- Newspaper article from: AIDS Vaccine Week November 24, 2008 700+ words
The question of whether or not to continue to pursue the development of T-cell-based HIV-1 vaccines has been a source of controversy following last year's widely publicized failure of the field's most promising...
